Lipid Metabolism and Lipoprotein Production in Kidney

肾脏中的脂质代谢和脂蛋白产生

• 批准号: 24659418
• 负责人: NATORI Yasuhiro
• 金额: $ 2.41万
• 依托单位: Iwate Medical University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Challenging Exploratory Research
• 财政年份: 2012
• 资助国家: 日本
• 起止时间: 2012 至 无数据
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-24659418/
• 关键词: 腎臓学; 腎尿細管上皮; 脂質代謝; アポリポタンパク質M

In normal condition, lipid accumulation is not observed in the kidney. In progressive kidney diseases, however, lipid is commonly accumulated in tubular epithelial cells of the kidney. We previously showed that LXR agonist, a drug known to activate lipid metabolism in the liver, reduced accumulated lipid in diseased kidney, and also urinary protein level in an animal model. In the present study, we have proposed that the induction of apolipoprotein M in the kidney by the drug is a part of its therapeutic effect for the kidney disease.

在正常情况下，肾脏中未观察到脂质蓄积。然而，在进行性肾脏疾病中，脂质通常积聚在肾脏的肾小管上皮细胞中。我们以前表明，LXR激动剂，一种已知激活肝脏脂质代谢的药物，减少了患病肾脏中的脂质积累，也减少了动物模型中的尿蛋白水平。在本研究中，我们提出了药物诱导肾脏中载脂蛋白M是其治疗肾脏疾病的一部分。